Russell Microcap Index

Femasys Inc. To Join the Russell Microcap® Index

Monday, September 20, 2021 - 9:05pm

The Russell MicrocapIndex is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.

Key Points: 
  • The Russell MicrocapIndex is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, please visit www.ftserussell.com .

Miromatrix Medical Added to Russell Microcap® Index

Monday, September 20, 2021 - 12:00pm

EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap Index, effective after the U.S. market opens today, September 20, 2021.

Key Points: 
  • EDEN PRAIRIE, Minn., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will be added to the Russell Microcap Index, effective after the U.S. market opens today, September 20, 2021.
  • The Russell Microcap Index measures the microcap segment of the U.S. equity market, consisting of the smallest 1,000 securities in the small-cap Russell 2000 Index, plus the next 1,000 smallest eligible securities by market cap.
  • "We are honored and thrilled to be a part of the Russell Microcap Index, and we believe the inclusion will increase our visibility and exposure with investors," said Jeff Ross, Ph.D., Miromatrix CEO.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website .

Richardson Electronics Selects SM Berger & Company, Inc. to Lead Strategic Investor Relations Program

Tuesday, September 14, 2021 - 4:00pm

Founded in 1984, SM Berger & Company has partnered with over 100 companies to develop and manage modern, integrated, and results-oriented investor relations and communications programs.

Key Points: 
  • Founded in 1984, SM Berger & Company has partnered with over 100 companies to develop and manage modern, integrated, and results-oriented investor relations and communications programs.
  • SM Berger & Company specializes in helping underfollowed small- and micro-cap companies across multiple industries engage with the capital markets.
  • SM Berger will oversee Richardson Electronics investor relations functions and serve as a key point of contact for shareholders.
  • About SM Berger & Company, Inc.
    As one of the nations oldest investor relations firms, SM Berger & Company, Inc. has helped over 100 small- and micro-cap companies develop and manage their investor relations programs, improve their communications, and increase their investor following.

iSpecimen Announces Inclusion in Russell Microcap® Index

Tuesday, September 14, 2021 - 1:00pm

Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

Key Points: 
  • Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.
  • Russell indexes are part of FTSE Russell, a leading global index provider.
  • "Our inclusion to the Russell Microcap Index is an important milestone and reflects iSpecimen's efforts and growth as we continue to streamline the biospecimen procurement process.
  • For more information on the Russell Microcap Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website .

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 2:48pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 1:03pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

Qualigen Therapeutics, Inc. Provides Update on Product Development Priorities and Reports Second Quarter and Six Month 2021 Financial Results

Tuesday, August 17, 2021 - 1:00pm

Qualigen also today announces its second quarter and six-months 2021 financial results and provides a recap of the highlights of the 2021 second quarter.

Key Points: 
  • Qualigen also today announces its second quarter and six-months 2021 financial results and provides a recap of the highlights of the 2021 second quarter.
  • Orphan Drug status, if obtained, would be expected to confer several advantages including faster review and increased market protection.
  • In May 2021, Qualigen announced that it had named Tariq Arshad, MD, MBA, to the newly-created position of Senior Vice President, Chief Medical Officer.
  • Revenues for the six month period ended June 30, 2021 were $3.0 million compared to $2.4 million in the same six month period of the previous year.

The Alkaline Water Company Records Another Record Quarter in Fiscal First Quarter 2022

Monday, August 16, 2021 - 9:10pm

The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the Company), the countrys largest independent alkaline water company, today announced record revenue of $14.1 million for the fiscal first quarter ended June 30, 2021.

Key Points: 
  • The Alkaline Water Company Inc. (NASDAQ and CSE: WTER) (the Company), the countrys largest independent alkaline water company, today announced record revenue of $14.1 million for the fiscal first quarter ended June 30, 2021.
  • Even when compared to last years pantry-loading, our first quarter fiscal 2022 was our 33rd straight comparable quarter of record sales.
  • Fiscal 2022 is shaping up to be a watershed year for The Alkaline Water Company.
  • About The Alkaline Water Company:
    Founded in 2012, The Alkaline Water Company (NASDAQ and CSE: WTER) is headquartered in Scottsdale, Arizona.

Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update

Thursday, August 12, 2021 - 10:15pm

HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have an unmet medical need condition, announces today financial results for the quarter ended June 30, 2021, and provides corporate update.

Key Points: 
  • HANOVER, Md., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have an unmet medical need condition, announces today financial results for the quarter ended June 30, 2021, and provides corporate update.
  • We also anticipate filing an IND in September for PCS12852 with site initiation beginning before year end.
  • Additionally, we expect interim data for PCS6422 in the fourth quarter of 2021 and interim data for PCS499 during the first half of 2022.
  • To participate in this event, please dial in approximately 5 to 10 minutes before the beginning of the call.

Applied Therapeutics Reports Second Quarter 2021 Financial Results

Thursday, August 12, 2021 - 12:00pm

NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2021.

Key Points: 
  • NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing
    NEW YORK, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2021.
  • Our pediatric Galactosemia program advanced significantly in the second quarter, said Shoshana Shendelman, PhD, CEO, Founder and Chair of the Board of Applied Therapeutics.
  • Applied Therapeutics plans to submit a New Drug Application (NDA) for Accelerated Approval of AT-007 for the treatment of Galactosemia in the third quarter of this year.
  • Net loss for the second quarter of 2021 was $25.8 million, or $0.99 per basic and diluted common share, compared to a net loss of $28.1 million, or $1.27 per basic and diluted common share, for the second quarter 2020.